| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Tom Solomon | Q18640365 |
| Julian Hiscox | Q40004586 | ||
| P2093 | author name string | Lisa F P Ng | |
| Mong-How Ooi | |||
| Jonathan A Cox | |||
| P2860 | cites work | Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity | Q21132297 |
| DNA vaccine constructs against enterovirus 71 elicit immune response in mice | Q21245503 | ||
| Mutation rates among RNA viruses | Q24643023 | ||
| Pathogen recognition and inflammatory signaling in innate immune defenses | Q24643034 | ||
| Innate Immunity and Immune Evasion by Enterovirus 71 | Q26773329 | ||
| Epidemiological Research on Hand, Foot, and Mouth Disease in Mainland China | Q26774357 | ||
| Neurotropic Enterovirus Infections in the Central Nervous System | Q26776541 | ||
| PAMPs and DAMPs: signal 0s that spur autophagy and immunity | Q27004190 | ||
| Structure of human enterovirus 71 in complex with a capsid-binding inhibitor | Q27676881 | ||
| Crystal Structure of Human Enterovirus 71 | Q27677574 | ||
| Neutralizing antibodies can initiate genome release from human enterovirus 71 | Q27681480 | ||
| IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway | Q28190704 | ||
| Scavenger receptor B2 is a cellular receptor for enterovirus 71 | Q28249350 | ||
| Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal Antibody | Q28550496 | ||
| Proteinase 2Apro Is Essential for Enterovirus Replication in Type I Interferon-Treated Cells | Q29039070 | ||
| Implications of Age-Dependent Immune Responses to Enterovirus 71 Infection for Disease Pathogenesis and Vaccine Design. | Q30382068 | ||
| Complete genome analysis of coxsackievirus A2, A4, A5, and A10 strains isolated from hand, foot, and mouth disease patients in China revealing frequent recombination of human enterovirus A. | Q30503122 | ||
| Treatment of potentially life-threatening enterovirus infections with pleconaril | Q31918011 | ||
| Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice | Q33602804 | ||
| A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved "knob" region of VP3 protein | Q33685512 | ||
| Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene | Q33725572 | ||
| Tyrosine Sulfation of the Amino Terminus of PSGL-1 Is Critical for Enterovirus 71 Infection | Q33747574 | ||
| Activation of JNK1/2 and p38 MAPK signaling pathways promotes enterovirus 71 infection in immature dendritic cells | Q33755064 | ||
| Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay | Q33806668 | ||
| Cytoplasmic viral RNA-dependent RNA polymerase disrupts the intracellular splicing machinery by entering the nucleus and interfering with Prp8 | Q33812774 | ||
| An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. | Q33875086 | ||
| Potent inhibition of human enterovirus 71 replication by type I interferon subtypes. | Q54388292 | ||
| Molecular and seroepidemiologic studies of Enterovirus 71 infection in the State of Para, Brazil. | Q54664679 | ||
| The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management | Q57105763 | ||
| Enterovirus 71 outbreak in Western Australia associated with acute flaccid paralysis. Preliminary report | Q57107855 | ||
| Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia | Q57108045 | ||
| Outbreak of Coxsackievirus A16 hand, foot, and mouth disease in a child day-care center | Q67770348 | ||
| Epidemiological, virological, and clinical features of an epidemic of hand, foot, and mouth disease in England and Wales | Q71146958 | ||
| Virological diagnosis of enterovirus type 71 infections: Experiences gained during an epidemic of acute CNS diseases in Hungary in 1978 | Q72939040 | ||
| Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease | Q73198212 | ||
| Duration of enterovirus shedding in stool | Q74630164 | ||
| Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group | Q77300551 | ||
| Breastfeeding provides passive and likely long-lasting active immunity | Q77804200 | ||
| Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides | Q79557916 | ||
| Hand, foot, and mouth disease associated with Coxsackie A9 virus | Q93728292 | ||
| Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. | Q40025566 | ||
| An outbreak of hand, foot and mouth disease in Bhubaneswar, Odisha | Q40043748 | ||
| Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling | Q33899320 | ||
| Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. | Q33932759 | ||
| The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. | Q34043450 | ||
| The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses | Q34046154 | ||
| The correlation between the presence of viremia and clinical severity in patients with enterovirus 71 infection: a multi-center cohort study | Q34048432 | ||
| Cell-specific proteins regulate viral RNA translation and virus-induced disease | Q34084984 | ||
| Clinical features, diagnosis, and management of enterovirus 71. | Q34144978 | ||
| Incidence rates of enterovirus 71 infections in young children during a nationwide epidemic in Taiwan, 2008-09. | Q34163871 | ||
| Enterovirus 71 outbreaks, Taiwan: occurrence and recognition | Q34184402 | ||
| 'Hand, foot, and mouth disease' associated with Coxsackie A5 virus | Q34253157 | ||
| Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial | Q34324574 | ||
| Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q34347924 | ||
| Enterovirus 71 infection: An experience in Korea, 2009 | Q34362945 | ||
| Immunodeficient mouse models with different disease profiles by in vivo infection with the same clinical isolate of enterovirus 71 | Q34593800 | ||
| Cross-reactive neutralizing antibody responses to enterovirus 71 infections in young children: implications for vaccine development | Q34607995 | ||
| An overview of the evolution of enterovirus 71 and its clinical and public health significance | Q34635602 | ||
| Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses | Q34649632 | ||
| Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication | Q34750642 | ||
| Detection of hand, foot and mouth disease in the yucatan peninsula of Mexico | Q34760345 | ||
| Workshop on use of intravenous immunoglobulin in hand, foot and mouth disease in Southeast Asia | Q34844126 | ||
| Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system | Q35114725 | ||
| Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated by Toll-like receptor 3. | Q35192859 | ||
| Host factors in enterovirus 71 replication | Q35383186 | ||
| Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. | Q35531212 | ||
| Far upstream element binding protein 1 binds the internal ribosomal entry site of enterovirus 71 and enhances viral translation and viral growth. | Q35617251 | ||
| Cytokine responses and correlations thereof with clinical profiles in children with enterovirus 71 infections | Q35658701 | ||
| The Role of VP1 Amino Acid Residue 145 of Enterovirus 71 in Viral Fitness and Pathogenesis in a Cynomolgus Monkey Model | Q35693536 | ||
| A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection | Q35702513 | ||
| Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection | Q35788059 | ||
| Selective human enterovirus and rhinovirus inhibitors: An overview of capsid-binding and protease-inhibiting molecules | Q35788236 | ||
| A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection | Q35826494 | ||
| Enterovirus co-infections and onychomadesis after hand, foot, and mouth disease, Spain, 2008. | Q35849010 | ||
| An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. | Q35948053 | ||
| Retrograde axonal transport: a major transmission route of enterovirus 71 in mice | Q35948100 | ||
| Epidemic of Hand, Foot and Mouth Disease Associated with Enterovirus 71 Infection | Q40123768 | ||
| An inactivated enterovirus 71 vaccine in healthy children | Q40216677 | ||
| Coxsackievirus B5 associated with hand-foot-mouth disease in a healthy adult | Q40240621 | ||
| Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria | Q40272154 | ||
| Clinical and epidemiologic features of Coxsackievirus A6 infection in children in northern Taiwan between 2004 and 2009. | Q40326826 | ||
| Type I interferons protect mice against enterovirus 71 infection | Q40349302 | ||
| Clinicopathologic analysis of atypical hand, foot, and mouth disease in adult patients | Q40393823 | ||
| Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives | Q40423924 | ||
| Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. | Q40458463 | ||
| Enterovirus 71 infection caused neuronal cell death and cytokine expression in cultured rat neural cells | Q40509621 | ||
| Human type I interferons: structure and function | Q40551674 | ||
| Clinical characteristics of an outbreak of hand, foot and mouth disease in Singapore | Q40555156 | ||
| Design, synthesis, and structure-activity relationships of pyrazolo[3,4-d]pyrimidines: a novel class of potent enterovirus inhibitors | Q40562779 | ||
| A murine oral enterovirus 71 infection model with central nervous system involvement | Q40600130 | ||
| Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group | Q40614108 | ||
| Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. | Q40628631 | ||
| Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors | Q40740581 | ||
| Receptors for enterovirus 71. | Q41188412 | ||
| Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus | Q41261599 | ||
| Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease | Q41988715 | ||
| Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China | Q42226974 | ||
| Tonsillar crypt epithelium is an important extra-central nervous system site for viral replication in EV71 encephalomyelitis | Q42246092 | ||
| Hand, foot, and mouth disease caused by coxsackievirus a6. | Q42425639 | ||
| The molecular basis of mouse adaptation by human enterovirus 71. | Q42659419 | ||
| Enterovirus 71: epidemiology, pathogenesis and management | Q43291847 | ||
| Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. | Q43464455 | ||
| Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. | Q43523822 | ||
| Human rhabdomyosarcoma cells for rapid detection of enteroviruses by shell-vial assay | Q43631453 | ||
| Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. | Q43981254 | ||
| Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. | Q44089905 | ||
| Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model | Q44103515 | ||
| Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system | Q44285689 | ||
| Pathogenesis study of enterovirus 71 infection in rhesus monkeys | Q44396938 | ||
| Transgenic expression of human P-selectin glycoprotein ligand-1 is not sufficient for enterovirus 71 infection in mice | Q44444682 | ||
| Outbreak of severe neurologic involvement associated with Enterovirus 71 infection | Q44881432 | ||
| A recurrent presentation of hand, foot, and mouth disease | Q44920101 | ||
| Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation | Q45078126 | ||
| Hand, Foot and Mouth Disease Associated with Coxsackievirus Group B | Q45298732 | ||
| Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement | Q45361800 | ||
| Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge | Q45396589 | ||
| Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus | Q45734536 | ||
| An apparently new enterovirus isolated from patients with disease of the central nervous system | Q46144493 | ||
| Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice | Q46354156 | ||
| Diverse apoptotic pathways in enterovirus 71-infected cells | Q46376571 | ||
| Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. | Q46550828 | ||
| Antiviral activity of pyridyl imidazolidinones against enterovirus 71 variants | Q46807540 | ||
| Mechanism of fulminant pulmonary edema caused by enterovirus 71. | Q47263332 | ||
| Development of murine monoclonal antibodies with potent neutralization effects on enterovirus 71. | Q47409667 | ||
| Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema | Q48235723 | ||
| Fatal enterovirus 71 encephalomyelitis | Q48335107 | ||
| Complete genome analysis of enterovirus 71 isolated from an outbreak in Taiwan and rapid identification of enterovirus 71 and coxsackievirus A16 by RT-PCR. | Q48344641 | ||
| In enterovirus 71 encephalitis with cardio-respiratory compromise, elevated interleukin 1β, interleukin 1 receptor antagonist, and granulocyte colony-stimulating factor levels are markers of poor prognosis | Q48429651 | ||
| Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. | Q50647112 | ||
| Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. | Q51129618 | ||
| Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. | Q51572981 | ||
| Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. | Q51797919 | ||
| Enterovirus 71 contains a type I IRES element that functions when eukaryotic initiation factor eIF4G is cleaved. | Q54378546 | ||
| Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. | Q36034012 | ||
| EV71 3D Protein Binds with NLRP3 and Enhances the Assembly of Inflammasome Complex | Q36242863 | ||
| P-Selectin glycoprotein ligand 1 (PSGL-1) is a physiological ligand for E-selectin in mediating T helper 1 lymphocyte migration. | Q36368299 | ||
| Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model | Q36483299 | ||
| Cleavage of interferon regulatory factor 7 by enterovirus 71 3C suppresses cellular responses | Q36559745 | ||
| Enterovirus 71 infection cleaves a negative regulator for viral internal ribosomal entry site-driven translation. | Q36759716 | ||
| Humanized mice for immune system investigation: progress, promise and challenges | Q37111994 | ||
| Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. | Q37157420 | ||
| A new animal model containing human SCARB2 and lacking stat-1 is highly susceptible to EV71 | Q37157440 | ||
| hnRNP A1 interacts with the 5' untranslated regions of enterovirus 71 and Sindbis virus RNA and is required for viral replication | Q37204562 | ||
| Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. | Q37247709 | ||
| Innate immunity to virus infection. | Q37361448 | ||
| Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells | Q37362417 | ||
| Viral and host proteins involved in picornavirus life cycle | Q37448468 | ||
| Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone | Q37489517 | ||
| Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. | Q37596057 | ||
| Virology, epidemiology, pathogenesis, and control of enterovirus 71. | Q37801742 | ||
| Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis | Q38028997 | ||
| Type I and III interferon production in response to RNA viruses. | Q38222524 | ||
| Enterovirus 2Apro targets MDA5 and MAVS in infected cells | Q38326170 | ||
| Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial | Q38474516 | ||
| A prospective, comparative study of severe neurological and uncomplicated hand, foot and mouth forms of paediatric enterovirus 71 infections | Q38822133 | ||
| Enterovirus 71 inhibits cellular type I interferon signaling by downregulating JAK1 protein expression | Q38987672 | ||
| Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice | Q39243456 | ||
| Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. | Q39253638 | ||
| Enterovirus 71 blocks selectively type I interferon production through the 3C viral protein in mice | Q39274465 | ||
| Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1 | Q39410081 | ||
| In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection | Q39412134 | ||
| Identification of a human SCARB2 region that is important for enterovirus 71 binding and infection. | Q39578725 | ||
| The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. | Q39827005 | ||
| Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. | Q39835244 | ||
| Enterovirus 71 outbreak, Brunei | Q39900119 | ||
| P921 | main subject | hand, foot and mouth disease | Q652744 |
| P304 | page(s) | 2249 | |
| P577 | publication date | 2017-11-28 | |
| P1433 | published in | Frontiers in Microbiology | Q27723481 |
| P1476 | title | Immunopathogenesis and Virus-Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease | |
| P478 | volume | 8 |
| Q89807228 | An infectious clone of enterovirus 71(EV71) that is capable of infecting neonatal immune competent mice without adaptive mutations |
| Q92322306 | Enterovirus 71 targets the cardiopulmonary system in a robust oral infection mouse model |
| Q78177416 | Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model. |
| Q59349670 | Immunocompetent and Immunodeficient Mouse Models for Enterovirus 71 Pathogenesis and Therapy |
| Q59353025 | Manipulation of Non-canonical NF-κB Signaling by Non-oncogenic Viruses |
| Q91725853 | Neutrophil extracellular traps induced by VP1 contribute to pulmonary edema during EV71 infection |
| Q61796005 | PLCβ2 negatively regulates the inflammatory response to virus infection by inhibiting phosphoinositide-mediated activation of TAK1 |
| Q90723595 | Sequence analysis of the first B5 subgenogroup strain of enterovirus 71 isolated in Korea |
| Q89983634 | TREM-1 activation is a potential key regulator in driving severe pathogenesis of enterovirus A71 infection |
| Q90709292 | Transcriptome sequencing analysis of SH-SY5Y cells infected with EV71 reveals the potential neuropathic mechanisms |
Search more.